GlassScriptPhysician profile
Meghan Skinner
NPI 1992150858
$3,589.31
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,450 · 2022: $1,296 · 2023: $617 · 2024: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $708.38 | 2021-2024 | |
| Abbvie INC. | $581.00 | 2021-2024 | |
| Amgen INC. | $499.19 | 2021-2023 | Aimovig |
| Biogen, INC. | $389.27 | 2021-2022 | |
| Ucb, INC. | $292.67 | 2021-2024 | Briviact |
| Kyowa Kirin, INC. | $225.17 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $161.33 | 2021 | |
| Alexion Pharmaceuticals, INC. | $140.39 | 2021-2022 | |
| Sk Life Science, INC. | $117.22 | 2021-2022 | |
| Lilly USA, LLC | $71.68 | 2021-2024 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $66.93 | 2022 | |
| Tanabe Pharma America, INC. | $65.81 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $47.58 | 2021-2022 | |
| Lundbeck LLC | $40.75 | 2021-2022 | |
| Allergan, INC. | $33.56 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.47 | 2021 | |
| Argenx US, INC. | $20.43 | 2022 | |
| Neurelis, INC. | $20.25 | 2022 | |
| Genentech USA, INC. | $18.02 | 2024 | Ocrevus |
| Pfizer INC. | $16.50 | 2023 | |
| Ge Healthcare | $15.63 | 2022 | |
| Neurocrine Biosciences, INC. | $13.22 | 2023 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $12.88 | 2022 | |
| Corium, LLC | $2.98 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.